Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA – Get Free Report) has been given an average recommendation of “Hold” by the six ratings firms that are presently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and two have issued a buy recommendation on the […]
Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA – Get Free Report) have been given a consensus rating of “Hold” by the six research firms that are currently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell rating, three have assigned a hold rating and two have assigned a buy rating to […]
StockNews.com upgraded shares of Enanta Pharmaceuticals (NASDAQ:ENTA – Free Report) from a sell rating to a hold rating in a research report sent to investors on Friday. Separately, JPMorgan Chase & Co. lowered their price target on Enanta Pharmaceuticals from $12.00 to $11.00 and set an underweight rating on the stock in a report on […]
Clearstead Advisors LLC bought a new position in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA – Free Report) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 5,064 shares of the biotechnology company’s stock, valued at approximately $57,000. Other institutional investors and hedge funds have […]
Enrollment Ongoing Across Three RSV Phase 2 Studies; Anticipates Announcing Topline Data for RSVPEDs and EDP-323 Challenge Study in Q3 2024Expanded into Immunology with New Discovery Program of Oral KIT Inhibitors for First Indication in Chronic Spontaneous Urticaria; Development Candidate Selection Targeted for 202.